Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

被引：233

作者：

Ibrahim, Amr R. ^{[1
]}

Eliasson, Lina ^{[1
]}

Apperley, Jane F. ^{[1
]}

Milojkovic, Dragana ^{[1
]}

Bua, Marco ^{[1
]}

Szydlo, Richard ^{[1
]}

Mahon, Francois-Xavier ^{[2
]}

Kozlowski, Kasia ^{[1
]}

Paliompeis, Christos ^{[1
]}

Foroni, Letizia ^{[1
]}

Khorashad, Jamshid S. ^{[1
]}

Bazeos, Alex ^{[1
]}

Molimard, Mathieu ^{[3
]}

Reid, Alistair ^{[1
]}

Rezvani, Katayoun ^{[1
]}

Gerrard, Gareth ^{[1
]}

Goldman, John ^{[1
]}

Marin, David ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London W12 0NN, England

[2] Univ Bordeaux 2, Lab Hematopoiese Leucem & Cible Therapeut, F-33076 Bordeaux, France

[3] Hosp Univ Bordeaux, Dept Clin Pharmacol & Toxicol, Bordeaux, France

来源：

BLOOD | 2011年 / 117卷 / 14期

关键词：

MOLECULAR RESPONSES; CHRONIC PHASE; NONADHERENCE; TAMOXIFEN;

D O I：

10.1182/blood-2010-10-309807

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We studied the relation between adherence to imatinib measured with microelectronic monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) and of imatinib failure in 87 CCyR chronic myeloid leukemia patients receiving long-term therapy. We included in our analysis the most relevant prognostic factors described to date. On multivariate analysis, the adherence rate and having failed to achieve a major molecular response were the only independent predictors for loss of CCyR and discontinuation of imatinib therapy. The 23 patients with an adherence rate less than or equal to 85% had a higher probability of losing their CCyR at 2 years (26.8% vs 1.5%, P = .0002) and a lower probability of remaining on imatinib (64.5% vs 90.6%, P = .006) than the 64 patients with an adherence rate more than 85%. In summary, we have shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy. (Blood. 2011; 117(14):3733-3736)

引用

页码：3733 / 3736

页数：4

共 15 条

[1] hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia [J].

Bazeos, A. ;

Marin, D. ;

Reid, A. G. ;

Gerrard, G. ;

Milojkovic, D. ;

May, P. C. ;

de Lavallade, H. ;

Garland, P. ;

Rezvani, K. ;

Apperley, J. F. ;

Goldman, J. M. ;

Foroni, L. ;

Khorashad, J. S. .

LEUKEMIA, 2010, 24 (06) :1243-1245

[2] Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].

Branford, S ;

Rudzki, Z ;

Harper, A ;

Grigg, A ;

Taylor, K ;

Durrant, S ;

Arthur, C ;

Browett, P ;

Schwarer, AP ;

Ma, D ;

Seymour, JF ;

Bradstock, K ;

Joske, D ;

Lynch, K ;

Gathmann, I ;

Hughes, TP .

LEUKEMIA, 2003, 17 (12) :2401-2409

[3] COMPLIANCE DECLINES BETWEEN CLINIC VISITS [J].

CRAMER, JA ;

SCHEYER, RD ;

MATTSON, RH .

ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (07) :1509-1510

[4] Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].

de Lavallade, Hugues ;

Apperley, Jane F. ;

Khorashad, Jamshid S. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363

[5]

Hughes TP, 2008, ASH ANN M, V112, P334

[6] Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy [J].

Kaeda, Jaspal ;

O'Shea, Derville ;

Szydlo, Richard M. ;

Olavarria, Eduardo ;

Dazzi, Francesco ;

Marin, David ;

Saunders, Susan ;

Khorashad, Jamshid S. ;

Cross, Nicholas C. P. ;

Goldman, John M. ;

Apperley, Jane F. .

BLOOD, 2006, 107 (10) :4171-4176

[7] Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib [J].

Marin, David ;

Bazeos, Alexandra ;

Mahon, Francois-Xavier ;

Eliasson, Lina ;

Milojkovic, Dragana ;

Bua, Marco ;

Apperley, Jane F. ;

Szydlo, Richard ;

Desai, Ritti ;

Kozlowski, Kasia ;

Paliompeis, Christos ;

Latham, Victoria ;

Foroni, Letizia ;

Molimard, Mathieu ;

Reid, Alistair ;

Rezvani, Katy ;

de Lavallade, Hugues ;

Guallar, Cristina ;

Goldman, John ;

Khorashad, Jamshid S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2381-2388

[8] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor [J].

Marin, David ;

Milojkovic, Dragana ;

Olavarria, Eduardo ;

Khorashad, Jamshid S. ;

de lavallade, Hugues ;

Reid, Alistair G. ;

Foroni, Letizia ;

Rezvani, Katayoun ;

Bua, Marco ;

Dazzi, Francesco ;

Pavlu, Jiri ;

Klammer, Matthias ;

Kaeda, Jaspal S. ;

Goldman, John M. ;

Apperley, Jane F. .

BLOOD, 2008, 112 (12) :4437-4444

[9] Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study [J].

Noens, Lucien ;

van Lierde, Marie-Anne ;

De Bock, Robrecht ;

Verhoef, Gregor ;

Zachee, Pierre ;

Berneman, Zwi ;

Martiat, Philippe ;

Mineur, Philippe ;

Van Eygen, Koen ;

MacDonald, Karen ;

De Geest, Sabina ;

Albrecht, Tara ;

Abraham, Ivo .

BLOOD, 2009, 113 (22) :5401-5411

[10] Drug therapy - Adherence to medication [J].

Osterberg, L ;

Blaschke, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (05) :487-497

← 1 2 →